COVID-19

AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients

AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients

Shots: The P-III (SUPERNOVA) study investigates the safety & efficacy of sipav...

Sanofi Partners with Novavax to Co-commercialize COVID-19 Vaccine and Develop Flu-COVID-19 Combination Vaccines

Sanofi Partners with Novavax to Co-commercialize COVID-19 Vaccine and Develop Flu-COVID-19 Combination Vaccines

Shots: Agreement grants co-exclusive rights to Sanofi to co-commercialize Novavax&...

Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms

Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms

Shots: The P-II/III (SCORPIO-SR) trial evaluates Ensitrelvir (125/250mg) vs PBO in...

Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19

Junshi Biosciences Reports the Result of VV116 in P-III to Treat COVID-19

Shots: The 2nd P-III study evaluating safety & efficacy of VV116 (mindeudesivi...

Senhwa Bioscience’s Silmitasertib Received the US FDA IND Approval to treat patients with community-acquired pneumonia (CAP)

Senhwa Bioscience’s Silmitasertib Received the US FDA IND Approval to treat patients with community-acquired pneumonia (CAP)

Shots: The US FDA approved P-II IND evaluating silmitasertib (CX-4945) that aimed...

Image